News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

One-third of metastatic breast ca patients develop brain mets

Apr 1, 2008
Caroline Helwick
Oncology NEWS InternationalOncology NEWS International Vol 17 No 4
Volume 17
Issue 4

About one-third of metastatic breast cancer patients with HER2 overexpression develop metastases to the brain, compared with 5% to 20% of the general metastatic breast cancer population, according to findings from a large observational study in newly diagnosed HER2-positive breast cancer.

SAN ANTONIO-About one-third of metastatic breast cancer patients with HER2 overexpression develop metastases to the brain, compared with 5% to 20% of the general metastatic breast cancer population, according to findings from a large observational study in newly diagnosed HER2-positive breast cancer.

Denise A. Yardley, MD, program director of breast cancer reserach at the Sarah Cannon Research Institute, Nashville, reported findings from the registHER study at the 2007 San Antonio Breast Cancer Symposium (abstract 6049).

RegistHER study

RegistHER is a multicenter prospective observational study of 1,023 patients, newly diagnosed with HER2-positive metastatic breast cancer, enrolled at 240 US sites from 2003 to 2006, who received treatment designed by their oncologists. The current analysis was restricted to the 768 patients diagnosed by July 1, 2005, thus allowing a median follow-up of 18 months from the occurrence of metastases at the time of data cut-off.

“Metastases in HER2-positive disease has been a big issue,” Dr. Yardley said. “This prospective study offers a unique opportunity to study the natural history of HER2-positive metastatic breast cancer and to examine treatment patterns and outcomes in a real-world setting.”

The fact that patients with HER2-positive metastatic breast cancer are more likely to develop central nervous system (CNS) metastases than those with HER2-negative disease has not been explained.

“The CNS has been a sanctuary site,” she said. “While trastuzumab [Herceptin] provides excellent systemic control, it does not cross the blood-brain barrier.”

A surprise

There is a theory, Dr. Yardley said, that CNS disease develops more often in HER2-positive patients because these patients obtain excellent disease control from trastuzumab [Herceptin] and thus live long enough for CNS disease to develop.

“But we did not find this,” she said. “In the registry, we found that CNS events occur very early, actually, mostly within the first year of the development of metastases. This was a bit of a surprise, and contrary to what we had thought.”

The analysis found that 236 patients (30.7%) developed CNS metastases over the 18 months of follow-up. This included 52 (6.8%) who had clinically apparent CNS metastases at the time of their initial metastatic breast cancer diagnosis, and 184 (23.9%) who developed CNS metastases as a later site of disease progression.

Patients who developed CNS metastases were younger (P = .0347), more likely to be hormone-receptor negative

(P = .0044), and had a higher disease burden (based on number of metastatic sites at diagnosis) (P = .0356), compared to patients without CNS metastases, Dr. Yardley reported.

Patients without clinically apparent CNS disease at presentation and who developed it during treatment for metastatic disease had a median time to the first CNS event of 12.1 months. Among the subset who had CNS metastases as their first and only site of progression after metastatic diagnosis, time to the first event was 11.3 months.

Median survival following the diagnosis of CNS metastases was 13.9 months. But for patients who had a CNS metastasis at the time of diagnosis, median survival was 36.1 months, Dr. Yardley reported.

Median survival time is considerably higher than would be expected, she added, based on the observation that survival of patients with brain metastases in other tumors is usually 4 to 6 months. “While HER2-positive patients are preferentially getting brain metastases earlier, they have prolonged survival,” she observed.

These observations are being explored. “It could be that brain metastases disrupt the blood-brain barrier, facilitating the delivery of effective treatments such as trastuzumab to this protected site,” she said. Other factors that could be contributing to prolonged survival include the marked improvements in radiation therapy techniques and treatment options.

Many patients who develop CNS metastases are switching to lapatinib (Tykerb), a molecule that is small enough to cross the blood-brain barrier. “We are waiting to see if this will continue to change the face of this disease,” she said.

Lapatinib plus capecitabine

In a phase II study reported at San Antonio (abstract 6076), Nancy Lin, MD, of Dana-Farber Cancer Center, said that the addition of capecitabine (Xeloda) to a lapatinib regimen in patients with CNS metastases is more active than lapatinib alone. The study was an updated analysis of EGF105084, presented at ASCO 2007 (abstract 1012), which involved 241 patients with CNS metastasis. The initial analysis found “modest activity” for lapatinib in protecting patients from the development of CNS metastases.

In EGF105084, patients were started on lapatinib 1,500 mg/d as monotherapy until disease progression; patients who progressed received lapatinib 1,250 mg/d plus capecitabine (Xeloda) 1,000 mg/m2 twice daily in an extension study. The CNS response, determined by MRI volumetric analysis, was the primary endpoint.

Updated analysis

In an updated analysis at SABCS, Dr. Lin reported that on lapatinib monotherapy CNS tumor volume was reduced by ≥ 50% in 6% of patients and ≥ 20% in 17% of patients. Median progression-free survival was 9.3 weeks.

In the 51 patients who received lapatinib plus capecitabine upon progression on lapatinib alone, the partial response rate was 20%, while 39% of patients achieved stable disease. CNS tumor volume was reduced by ≥ 50 in 20% of patients and by ≥ 20% in 37% of patients. Median progression-free survival was 15.8 weeks.

Absolute volumetric reductions were more than twice as great with the combination as with lapatinib alone.

“These reductions in the size of recurrent brain metastases occurred without progression of non-CNS disease, increase in steroid requirements, or worsening of neurological signs of symptoms,” Dr. Lin noted.

It is possible, she said, that the CNS responses observed in the EGF105084 extension arm were entirely a result of capecitabine.

“However, it is equally possible that the activity is at least partially a consequence of coadministration,” she said.

Dr. Lin bases this conclusion on the synergy observed between HER2- directed therapy and chemotherapy, and the results of the previous EGF100151 trial, in which the combination was associated with higher response rates and longer progression-free survival, and (in an exploratory analysis) fewer CNS progression events than occurred with capecitabine alone.

Articles in this issue

Proton therapy training offered
Editor of Blood reviews a very bloody movie
Artists take note: Oncology on Canvas accepting entries
PET affects treatment in over one-third of cancer cases
Expanded use of Axxent approved
Gardasil supplemental application gets priority review designation
Optical tomo/US monitors adjuvant chemo response
GIST patients resistant to imatinib/sunitinib respond to sorafenib
Sunitinib plus a taxane active in advanced breast cancer
Stanford V yields excellent outcomes in bulky, advanced HL
Monica Morrow joins Memorial Sloan-Kettering Cancer Center
Nereus initiates phase 1b trial of NPI-2358 in NSCLC patients
LHRH agonist use declines after reimbursement cuts
Palliative care helps pediatric pts at end of life
New colon screening guideline includes CT colonography
Related Videos
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.
Experts on breast cancer
Experts on breast cancer
Experts on breast cancer
Hope S. Rugo, MD, an expert on breast cancer
Related Content

Lasofoxifene Combo Yields Meaningful Activity in ER+/HER2– Breast Cancer

June 6th 2023

Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment

May 8th 2023

HER3-DXd Yields Positive Efficacy/Safety Profile in Breast Cancer

June 5th 2023

Oncology On-The-Go Podcast: Time to Treatment for Breast Cancer in Rural Populations

February 27th 2023

Elacestrant Improves PFS Vs SOC in ER+/HER2– Advanced Breast Cancer

June 4th 2023

Abemaciclib Combo Maintains Efficacy in Older HER2– Breast Cancer Population

June 3rd 2023

Lasofoxifene Combo Yields Meaningful Activity in ER+/HER2– Breast Cancer

June 6th 2023

Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment

May 8th 2023

HER3-DXd Yields Positive Efficacy/Safety Profile in Breast Cancer

June 5th 2023

Oncology On-The-Go Podcast: Time to Treatment for Breast Cancer in Rural Populations

February 27th 2023

Elacestrant Improves PFS Vs SOC in ER+/HER2– Advanced Breast Cancer

June 4th 2023

Abemaciclib Combo Maintains Efficacy in Older HER2– Breast Cancer Population

June 3rd 2023

Lasofoxifene Combo Yields Meaningful Activity in ER+/HER2– Breast Cancer

June 6th 2023

Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment

May 8th 2023

HER3-DXd Yields Positive Efficacy/Safety Profile in Breast Cancer

June 5th 2023

Oncology On-The-Go Podcast: Time to Treatment for Breast Cancer in Rural Populations

February 27th 2023

Elacestrant Improves PFS Vs SOC in ER+/HER2– Advanced Breast Cancer

June 4th 2023

Abemaciclib Combo Maintains Efficacy in Older HER2– Breast Cancer Population

June 3rd 2023
Related Content

The anti-tumor activity of lasofoxifene plus abemaciclib does not appear to be compromised by co-occurring alterations that confer resistance among patients with estrogen receptor–positive HER2-negative breast cancer.

Lasofoxifene Combo Yields Meaningful Activity in ER+/HER2– Breast Cancer

June 6th 2023
Article

The anti-tumor activity of lasofoxifene plus abemaciclib does not appear to be compromised by co-occurring alterations that confer resistance among patients with estrogen receptor–positive HER2-negative breast cancer.


Rakhshanda Rahman, MD, FRCS, FACS, emphasizes educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment

May 8th 2023
Podcast

Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.


An improved efficacy response resulted from the use of patritumab deruxtecan to treat patients who had been heavily pretreated for metastatic breast cancer.

HER3-DXd Yields Positive Efficacy/Safety Profile in Breast Cancer

June 5th 2023
Article

Treatment with patritumab deruxtecan appears to yield improved responses in patients who have been heavily pretreated for metastatic breast cancer.


Minh-Tri Nguyen, MD, spoke with CancerNetwork® about differences between time to treatment, socioeconomic status, and clinical outcomes in rural and urban patients with breast cancer.

Oncology On-The-Go Podcast: Time to Treatment for Breast Cancer in Rural Populations

February 27th 2023
Podcast

Minh-Tri Nguyen, MD, spoke with CancerNetwork® about differences between time to treatment, socioeconomic status, and clinical outcomes in rural and urban patients with breast cancer.


Elacestrant also appears to produce a manageable safety profile in the treatment of patients with estrogen receptor–positive HER2-negative advanced breast cancer in the phase 3 EMERALD trial.

Elacestrant Improves PFS Vs SOC in ER+/HER2– Advanced Breast Cancer

June 4th 2023
Article

Elacestrant also appears to produce a manageable safety profile in the treatment of patients with estrogen receptor–positive HER2-negative advanced breast cancer in the phase 3 EMERALD trial.


Older patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer maintain a clinically meaningful absolute reduction in risk of distant relapse and invasive disease following treatment with abemaciclib and endocrine therapy.

Abemaciclib Combo Maintains Efficacy in Older HER2– Breast Cancer Population

June 3rd 2023
Article

Older patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer maintain a clinically meaningful absolute reduction in risk of distant relapse and invasive disease following treatment with abemaciclib and endocrine therapy.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.